Acute Kidney Injury Treatment Market (AKI) by Product (Dialysis, Drug Therapy), Injury Type (Intrinsic-Renal Acute Kidney Injury, Post-Renal Acute Kidney Injury, Pre-Renal Acute Kidney Injury), End-User - Global Forecast 2024-2030

Acute Kidney Injury Treatment Market (AKI) by Product (Dialysis, Drug Therapy), Injury Type (Intrinsic-Renal Acute Kidney Injury, Post-Renal Acute Kidney Injury, Pre-Renal Acute Kidney Injury), End-User - Global Forecast 2024-2030

The Acute Kidney Injury Treatment Market size was estimated at USD 1.87 billion in 2023 and expected to reach USD 2.02 billion in 2024, at a CAGR 7.81% to reach USD 3.17 billion by 2030.

Acute kidney injury (AKI) treatment refers to the provision of therapeutic solutions, devices, and services for the management and recovery of patients suffering from acute kidney injury, a sudden case of kidney damage or failure. Treatment options include various pharmaceutical drugs, dialysis equipment, advanced treatment modalities, and supportive care services aimed at restoring normal kidney function and preventing further complications. The application of AKI treatment encompasses various clinical settings such as hospitals, intensive care units (ICUs), nephrology clinics, and home healthcare. The increasing prevalence of conditions leading to AKI and a growing elderly population vulnerable to AKI have necessitated the deployment of immediate treatment solutions. Additionally, technological advancements in diagnostic tools, therapies and rising healthcare expenditure have expanded the provision of treatment services. However, the lack of reimbursements for treatment options and the high cost of availing treatment for AKI may limit the accessibility of treatment options. Stringent regulatory policies leading to longer approval times and delayed commercialization of new products also pose concerns. However, manufacturers and biotechnological companies are exploring options to ease the regulatory approval process. It is crucial for businesses operating in this segment to invest in research and development with a focus on innovation.

Regional Insights

In the Americas, the United States is associated with advanced technological innovations that cater to the aging population with an increased risk of kidney diseases. The Americas region is characterized by the presence of government initiatives to expand AKI treatment options. The European Union witnesses a consistent need for novel AKI treatments due to increasing occurrences of CKD among its citizens. European nations, including Germany, France, and the UK, have robust biotechnology and pharmaceutical companies that are constantly innovating and exploring novel treatment options. China, Japan, and India have a significant need for AKI treatment owing to their large population base and increasing prevalence of kidney-related disorders. The Chinese government has launched several initiatives to enhance healthcare access, which, in turn, is expected to boost the demand for AKI treatments. Japan also exhibits a significant market potential due to its rapidly aging population and advanced healthcare infrastructure.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Acute Kidney Injury Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Rising number of kidney failures and kidney-related diseases
• Growing number of drug approvals for the treatment of kidney disorders
• Government initiatives to raise awareness about kidney health

Market Restraints

• High cost of availing treatment and lack of reimbursements

Market Opportunities

• Advancements to enhance kidney treatment options and improve disease detection
• New hospitals providing kidney treatment and improvements in outpatient care

Market Challenges

• Stringent regulations concerning certain kidney injury treatment options

Market Segmentation Analysis

• Product: Rising number of research initiatives to improve dialysis treatment
• Injury type: Awareness about underlying causes of kidney injury leading to the creation of treatments for Intrinsic-Renal Acute Kidney Injury
• End-user: Improvements in outpatient care leading to rising prevalence of ambulatory surgical centers (ASCs)

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Acute Kidney Injury Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Acute Kidney Injury Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Novartis to Buy Chinook for Up to USD 3.5 Billion, Expanding Kidney Disease Pipeline

Novartis AG reached an agreement to acquire Chinook Therapeutics for a potential sum of USD 3.5 billion. This acquisition is aimed to expand Novartis' renal pipeline by incorporating two late-stage programs that target rare and severe chronic kidney diseases.

CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

CalciMedica Inc. and Graybug Vision, Inc. completed their merger to enhance their product portfolio. The combined company's primary focus is aimed to be development of its lead product candidate, Auxora, a novel intravenous-formulated small molecule CRAC channel inhibitor designed to treat life-threatening inflammatory diseases.

SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury

SeaStar Medical, a medical device company, received approval from the U.S. Food and Drug Administration (FDA) for their Investigational Device Exemption (IDE) application. This IDE is expected to be used to assess the efficacy of their Selective Cytopheretic Device (SCD) in reducing hyperinflammation in adults with acute kidney injury.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Acute Kidney Injury Treatment Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Acute Kidney Injury Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alloksys Life Sciences B.V., Amgen Inc., Angion Biomedica Corp., Asahi Kasei Medical Co., Ltd., B. Braun Melsungen AG, Baxter International, Inc., Bayer AG, bioMérieux SA, Dr. Reddys Laboratories Ltd., Fresenius Medical Care AG & Co. KGaA, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Reata Pharmaceuticals Inc. by Biogen Inc., Rockwell Medical, Inc., Silver Creek Pharmaceuticals, Inc., Stealth BioTherapeutics, Inc., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Acute Kidney Injury Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
• Dialysis
• Continuous Renal Replacement Therapy (CRRT)
• Intermittent Hemodialysis
• Sustained Low-Efficiency Dialysis (SLED)
• Drug Therapy
• Antibiotics
• Diuretics
• Immunosuppressive Agents
• Injury Type
• Intrinsic-Renal Acute Kidney Injury
• Post-Renal Acute Kidney Injury
• Pre-Renal Acute Kidney Injury
• End-User
• Ambulatory Surgical Centers
• Hospitals
• Region
• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year